Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 1/20 | 0.52 |
| ▸ | VNN1 | O95497 | 1/20 | 0.45 |
| ▸ | PDE2A | O00408 | 1/20 | 0.45 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.45 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.44 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 3/20 | 0.43 |
| ▸ | ELANE | P08246 | 2/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | CCR3 | P51677 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4916897 | 1.00 | HCRTR1 (0.52) | HCRTR1VNN1PDE2AENPP2SPHK2 | |
| SCHEMBL4919265 | 0.86 | HCRTR1 (0.52) | HCRTR1PDE2ACCR3 | |
| SCHEMBL4919272 | 0.86 | HCRTR1 (0.52) | HCRTR1PDE2ACCR3 | |
| SCHEMBL3570468 | 0.85 | HCRTR1 (0.49) | HCRTR1PDE2ACCR3 | |
| SCHEMBL3570473 | 0.85 | HCRTR1 (0.49) | HCRTR1PDE2ACCR3 | |
| SCHEMBL15064844 | 0.82 | HCRTR1 (0.58) | HCRTR1PDE2ACNR2CCR3 | |
| SCHEMBL15064842 | 0.82 | HCRTR1 (0.53) | HCRTR1PDE2ACNR2RAB9ACCR3 | |
| SCHEMBL3575371 | 0.81 | HCRTR1 (0.51) | HCRTR1PDE2ACNR2NPC1RAB9A | |
| SCHEMBL3575368 | 0.81 | HCRTR1 (0.51) | HCRTR1PDE2ACNR2NPC1RAB9A | |
| SCHEMBL13570575 | 0.81 | NPC1 (0.43) | HCRTR1VNN1ENPP2SPHK2SPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269282-A1 | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof | GENMEDICA THERAPEUTICS SL (ES) | 2008-10-30 | — | — | US | claimed |
| JP-2008508348-A | — | — | 2008-03-21 | — | — | JP | claimed |
| EP-1796681-A2 | COMPOUNDS FOR INHIBITING COPPER-CONTAINING AMINE OXIDASES AND USES THEREOF | Genmedica Therapeutics SL (ES) | 2007-06-20 | — | — | EP | claimed |
| US-20070066646-A1 | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof | GENMEDICA THERAPEUTICS SL (ES) | 2007-03-22 | — | — | US | claimed |
| WO-2006013209-A2 | COMPOUNDS FOR INHIBITING COPPER-CONTAINING AMINE OXIDASES AND USES THEREOF | GENMEDICA THERAPEUTICS SL (ES) | 2006-02-09 | — | — | WO | claimed |
| US-20080269282-A1 | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof | GENMEDICA THERAPEUTICS SL (ES) | 2008-10-30 | — | — | US | disclosed |
| US-20070066646-A1 | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof | GENMEDICA THERAPEUTICS SL (ES) | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269282-A1 | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof | AOC2, AOC3, AOC1 | HCRTR1 975/4885VNN1 502/4885PDE2A 3732/4885 |
| US-20070066646-A1 | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof | AOC2, AOC3, AOC1 | HCRTR1 967/4885VNN1 702/4885PDE2A 3633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.